開示日時:2022/03/30 09:00:00
損益
決算期 | 売上高 | 営業益 | 経常益 | EPS |
2018.03 | 46,683,800 | 8,817,300 | 8,817,300 | 134.53 |
2019.03 | 45,926,700 | 5,788,400 | 5,788,400 | 122.39 |
2020.03 | 48,273,200 | 8,323,900 | 8,323,900 | 102.58 |
2021.03 | 51,595,200 | 7,122,400 | 7,122,400 | 141.5 |
※金額の単位は[万円]
株価
前日終値 | 50日平均 | 200日平均 | 実績PER | 予想PER |
1,407.0 | 1,409.62 | 1,874.71 | 9.83 | 11.12 |
※金額の単位は[円]
キャッシュフロー
決算期 | フリーCF | 営業CF |
2018.03 | 8,106,600 | 9,342,000 |
2019.03 | 3,579,700 | 4,871,100 |
2020.03 | 3,277,700 | 4,612,800 |
2021.03 | 12,479,500 | 13,560,100 |
※金額の単位は[万円]
▼テキスト箇所の抽出
March 30, 2022 Sumitomo Dainippon Pharma Co., Ltd. Notice of Establishment of Holding Company in China Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced that its Board of Directors resolved at a meeting held on February 28, 2022, to establish a holding company in China as a wholly owned subsidiary. 1. Objective of the establishment The Company decided to establish a holding company, “Sumitomo Pharma (China) Co., Ltd.” in China as a wholly owned subsidiary to manage and enhance our China business. 2. Outline of the subsidiary (1) Company name: Sumitomo Pharma (China) Co., Ltd. (2) Location: 7th Floor, Tower A, China Overseas International Center, Lane 838, South Huangpi Road, Huangpu District, Shanghai (3) Representative: Yoshitaka Koketsu (Chairman of the Board) (4) Function: Manage the Company’s China business as a holding company The impact of the establishment of the holding company on the Company’s consolidated financial ・General management ・Shared service ・Cash pool (5) Share capital: 30M US dollars (6) Establishment: May 2022 (TBD) (7) Ownership: 100% owned by the Company (8) Fiscal year-end: December 31 (9) Number of employees: 15(TBD) 3. Future outlook results is minimal. Contact: Corporate Communications Sumitomo Dainippon Pharma Co., Ltd. TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)